×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
KZR – kezar life sciences, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
KZR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/14
10:12 am
kzr
Kezar Life Sciences, Inc. (NASDAQ: KZR) had its price target lowered by analysts at Wells Fargo & Company from $20.00 to $11.00. They now have an "equal weight" rating on the stock.
Low
Report
Kezar Life Sciences, Inc. (NASDAQ: KZR) had its price target lowered by analysts at Wells Fargo & Company from $20.00 to $11.00. They now have an "equal weight" rating on the stock.
11/13
08:36 am
kzr
Kezar Life Sciences, Inc. (NASDAQ: KZR) had its "market perform" rating re-affirmed by analysts at William Blair.
Medium
Report
Kezar Life Sciences, Inc. (NASDAQ: KZR) had its "market perform" rating re-affirmed by analysts at William Blair.
11/12
04:41 pm
kzr
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
11/12
04:01 pm
kzr
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Low
Report
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
11/5
10:58 am
kzr
Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)
Low
Report
Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)
10/28
08:30 am
kzr
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split
Medium
Report
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split
10/17
01:43 pm
kzr
Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study [Yahoo! Finance]
Low
Report
Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study [Yahoo! Finance]
10/17
08:35 am
kzr
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan
Medium
Report
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
04:08 pm
kzr
Form 8-K Kezar Life Sciences, For: Nov 13
Low
Report
Form 8-K Kezar Life Sciences, For: Nov 13
11/14
12:25 pm
kzr
Form SCHEDULE 13G/A Kezar Life Sciences, Filed by: BARCLAYS PLC
Low
Report
Form SCHEDULE 13G/A Kezar Life Sciences, Filed by: BARCLAYS PLC
11/12
04:19 pm
kzr
Form 10-Q Kezar Life Sciences, For: Sep 30
Low
Report
Form 10-Q Kezar Life Sciences, For: Sep 30
11/12
04:07 pm
kzr
Form 8-K Kezar Life Sciences, For: Nov 12
Low
Report
Form 8-K Kezar Life Sciences, For: Nov 12
10/28
04:07 pm
kzr
Form 8-K Kezar Life Sciences, For: Oct 28
Medium
Report
Form 8-K Kezar Life Sciences, For: Oct 28
10/17
09:23 am
kzr
Form 8-A12B Kezar Life Sciences,
Low
Report
Form 8-A12B Kezar Life Sciences,
10/17
08:48 am
kzr
Form 8-K Kezar Life Sciences, For: Oct 17
Medium
Report
Form 8-K Kezar Life Sciences, For: Oct 17
10/10
08:42 am
kzr
Form 8-K Kezar Life Sciences, For: Oct 10
Medium
Report
Form 8-K Kezar Life Sciences, For: Oct 10
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/5
Form 4 Kezar Life Sciences, For: Feb 04 Filed by: Economides Vassiliki
28.2%
1/30 Form 8-K Kezar Life Sciences, For: Jan 30 26.9%
2/10 Form SC 13G/A Kezar Life Sciences, Filed by: AMGEN INC 24.0%
4/9 Kezar Provides Statement Regarding COVID-19 Pandemic 9.7%
12/19 Form 3 Kezar Life Sciences, For: Dec 18 Filed by: Garner Elizabeth 8.4%
6/27 Form 4 Kezar Life Sciences, For: Jun 25 Filed by: BERGER FRANKLIN M 7.5%
10/1 Kezar Life Sciences Announces Presentations of Four Abstracts at the 2019 ACR/ARP Annual Meeting 6.8%
12/19 Kezar Life Sciences Enhances Clinical Expertise with the Appointment of Elizabeth Garner, MD, MPH to its Board of Directors 6.3%
8/12 Form 4 Kezar Life Sciences, For: Aug 09 Filed by: Fowler John Franklin 6.2%
12/20 Form 4 Kezar Life Sciences, For: Dec 19 Filed by: Fowler John Franklin 5.7%
1/30 Form 8-K Kezar Life Sciences, For: Jan 30 26.9%
2/10 Form SC 13G/A Kezar Life Sciences, Filed by: AMGEN INC 24.0%
4/9 Kezar Provides Statement Regarding COVID-19 Pandemic 9.7%
12/19 Form 3 Kezar Life Sciences, For: Dec 18 Filed by: Garner Elizabeth 8.4%
6/27 Form 4 Kezar Life Sciences, For: Jun 25 Filed by: BERGER FRANKLIN M 7.5%
10/1 Kezar Life Sciences Announces Presentations of Four Abstracts at the 2019 ACR/ARP Annual Meeting 6.8%
12/19 Kezar Life Sciences Enhances Clinical Expertise with the Appointment of Elizabeth Garner, MD, MPH to its Board of Directors 6.3%
8/12 Form 4 Kezar Life Sciences, For: Aug 09 Filed by: Fowler John Franklin 6.2%
12/20 Form 4 Kezar Life Sciences, For: Dec 19 Filed by: Fowler John Franklin 5.7%
TOP News Decliners
5/28
Kezar Life Sciences Announces Acceptance of Abstract for Presentation of First in Patient Study with KZR-616 at EULAR 2019 Annual Meeting
-34.0%
2/26 Kezar Life Sciences to Present at Cowen and Company’s 40th Annual Healthcare Conference -14.2%
2/7 Form SC 13G/A Kezar Life Sciences, Filed by: FMR LLC -12.9%
6/13 Form 8-K Kezar Life Sciences, For: Jun 13 -12.5%
11/12 Kezar Announces Promising New Data with KZR-616 at the American College of Rheumatology Annual Meeting -11.2%
3/10 Form SC 13G/A Kezar Life Sciences, Filed by: FMR LLC -11.0%
10/1 Kezar Life Sciences Inc (NASDAQ: KZR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.50 price target on the stock. -10.1%
3/14 Kezar Life Sciences Inc (NASDAQ: KZR) had its "buy" rating re-affirmed by analysts at William Blair. -7.7%
3/13 Kezar Life Sciences Inc (NASDAQ: KZR) had its price target lowered by analysts at Wells Fargo & Co from $30.00 to $18.00. They now have an "overweight" rating on the stock. -7.4%
6/25 Form 8-K Kezar Life Sciences, For: Jun 25 -7.1%
2/26 Kezar Life Sciences to Present at Cowen and Company’s 40th Annual Healthcare Conference -14.2%
2/7 Form SC 13G/A Kezar Life Sciences, Filed by: FMR LLC -12.9%
6/13 Form 8-K Kezar Life Sciences, For: Jun 13 -12.5%
11/12 Kezar Announces Promising New Data with KZR-616 at the American College of Rheumatology Annual Meeting -11.2%
3/10 Form SC 13G/A Kezar Life Sciences, Filed by: FMR LLC -11.0%
10/1 Kezar Life Sciences Inc (NASDAQ: KZR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.50 price target on the stock. -10.1%
3/14 Kezar Life Sciences Inc (NASDAQ: KZR) had its "buy" rating re-affirmed by analysts at William Blair. -7.7%
3/13 Kezar Life Sciences Inc (NASDAQ: KZR) had its price target lowered by analysts at Wells Fargo & Co from $30.00 to $18.00. They now have an "overweight" rating on the stock. -7.4%
6/25 Form 8-K Kezar Life Sciences, For: Jun 25 -7.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: